Order Article Reprints

Ang YLE, Zhao X, Reungwetwattana T, Cho B-C, Liao B-C, Yeung R, Loong HH, Kim D-W, Yang JC-H, Lim SM, et al. A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study). Cancers. 2023; 15(20):4999. https://doi.org/10.3390/cancers15204999

Ang, Yvonne L. E., Xiaotian Zhao, Thanyanan Reungwetwattana, Byoung-Chul Cho, Bin-Chi Liao, Rebecca Yeung, Herbert H. Loong, Dong-Wan Kim, James Chih-Hsin Yang, Sun Min Lim, and et al. 2023. "A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study)" Cancers 15, no. 20: 4999. https://doi.org/10.3390/cancers15204999

Ang, Y. L. E., Zhao, X., Reungwetwattana, T., Cho, B.-C., Liao, B.-C., Yeung, R., Loong, H. H., Kim, D.-W., Yang, J. C.-H., Lim, S. M., Ahn, M.-J., Lee, S.-H., Suwatanapongched, T., Kongchauy, K., Ou, Q., Yu, R., Tai, B. C., Goh, B. C., Mok, T. S. K., & Soo, R. A. (2023). A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study). Cancers, 15(20), 4999. https://doi.org/10.3390/cancers15204999